GlassScriptPhysician profile
Kofi Clarke
NPI 1841254851
$425,881.09
in general payments reported to CMS, 2019-2025
14 companies · $91K in 2025
The $91K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $19K · 2021: $48K · 2022: $55K · 2023: $55K · 2024: $79K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Consulting Fee: $44K · Travel and Lodging: $10K · Food and Beverage: $4,534 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $167,000.38 |
| Consulting Fee | $43,575.00 |
| Travel and Lodging | $10,196.36 |
| Food and Beverage | $4,533.56 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $129,212.83 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $82,450.64 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $79,141.33 | 2019-2022 | |
| Abbvie INC. | $73,986.46 | 2019-2025 | Creon, Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $57,303.89 | 2019-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $3,500.00 | 2022 | |
| Janssen Research & Development, LLC | $122.38 | 2024 | |
| Celgene Corporation | $110.01 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.05 | 2024 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $15.70 | 2019 | |
| Braintree Laboratories, INC. | $12.80 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kofi Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.